BeOne Medicines AG (BVMF:B1ME34)

Market Cap	166.99B +7.1%
Revenue (ttm)	29.76B +29.9%
Net Income	2.78B
EPS	23.57
Shares Out	n/a
PE Ratio	59.98
Forward PE	41.95
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	319
Open	62.16
Previous Close	62.16
Day's Range	62.16 - 62.16
52-Week Range	52.60 - 72.73
Beta	n/a
RSI	46.50
Earnings Date	Aug 31, 2026

About BeOne Medicines AG

BeOne Medicines AG, an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company’s commercial stage products include BRUKINSA, a small molecule inhibitor of Bruton’s Tyrosine Kinase (BTK) for the treatment of various blood cancers; TEVIMBRA, an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; SYLVANT for the treatment of adult patients with multicentric castleman disease; BAITUOWEI for patients w...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2010
• Employees: 12,000
• Stock Exchange: Brazil Stock Exchange
• Ticker Symbol: B1ME34

Financial Performance

Financial numbers in CNY